A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
Clinical trial NCT06563505 · RECRUITING
Trial details
- NCT number
- NCT06563505
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-11
- Primary completion
- 2026-12-31
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.